Biotricity Produces Largest Inventory in its History to Meet Accelerated Demand

Core Viewpoint - Biotricity Inc. has successfully secured the necessary capital from its term lender and existing investors to achieve profitability without requiring future financing [2][3][5]. Financial Health - The company completed financings totaling $811 thousand through promissory and convertible promissory notes, alongside $635 thousand from additional term loan proceeds [4]. - Interest relief was provided through the capitalization of $945 thousand due on the company's pre-existing term loan [4]. Operational Efficiency - Biotricity has achieved positive Free Cash Flow, a key metric towards profitability, which has garnered confidence from investors and lenders [3]. - The company has invested in its largest manufacturing order to date, which is expected to fulfill anticipated sales orders in 2025 [5]. - The proprietary AI workflow engine has improved operational capacity by 50%, with an expected further improvement of 15% [6]. Future Outlook - The company anticipates that the additional revenue from selling inventory and connected SaaS-based technology will augment its positive Free Cash Flows, aiming for full profitability within the next calendar year [5]. - The next generation AI cloud is expected to improve Cost of Goods Sold (COGS) across the SaaS business by 5% post FDA clearance, contributing to future profits [6].